investor area
Matchgénica operates under a robust B2B SaaS model, which has already generated more than €2.5 million in annual recurring revenue (AAR) through the distribution of 189 active and 113 extended licenses among research centers, hospitals and clinical trials.
We have a consolidated presence in Spain (88%) and in Latin America, Colombia and Chile (12%), and we have an active LLC in the United States to support our international expansion strategy.
In the last 3 years, we have reached 3.8 million euros in accumulated revenues, thanks to alliances with key institutions such asHospital Virgen del Rocío, Quirónsalud, Universidad de Sevilla, Hospital La Paz, among others.
Our seed round of 2.1 million euros was 100% closed in December 2024, allowing us to focus on version integration, regulatory certification, team expansion and business expansion.
